Paras Healthcare IPO Analysis 2026: Price, Valuation, Financials, Risks & Key Details

Paras Healthcare Ltd is launching its ₹1,450 crore IPO on 21 October 2026, with a price band of ₹660 to ₹693 per share. The hospital chain reported 24.10% revenue growth in FY26 and returned to profitability after two loss-making years. However, its high valuation, substantial borrowings and ₹950 crore Offer for Sale (OFS) remain important considerations.

This Paras Healthcare IPO Analysis 2026 examines the company's financial performance, hospital occupancy, debt position, IPO valuation, growth opportunities and key risks to help investors understand the offering.

Table of Contents

1. Paras Healthcare IPO Details
2. Paras Healthcare IPO Issue Structure
3. Paras Healthcare IPO Objectives and Use of Proceeds
4. About Paras Healthcare Ltd
5. Paras Healthcare Financial Performance
6. Hospital Occupancy and ARPOB Analysis
7. Paras Healthcare Debt and Cash Flow Analysis
8. Paras Healthcare IPO Valuation and Peer Comparison
9. Growth Opportunities and Expansion Plans
10. Paras Healthcare IPO GMP
11. Strengths and Key Risks
12. Paras Healthcare IPO Review: What Investors Should Track

Paras Healthcare IPO Details

The Paras Healthcare IPO is a book-built mainboard issue comprising fresh equity shares and an Offer for Sale by existing shareholders.

The subscription period runs from 21 to 23 October 2026, with the company proposing to list on both the BSE and NSE.

Particulars	Details
Company	Paras Healthcare Ltd
IPO issue size	₹1,450 crore
Fresh issue	₹500 crore
Offer for Sale	₹950 crore
Paras Healthcare IPO price band	₹660 to ₹693
Face value	₹1 per share
Lot size	21 shares
Minimum retail investment	₹14,553
IPO opening date	21 October 2026
IPO closing date	23 October 2026
Allotment date	26 October 2026 (tentative)
Listing date	28 October 2026 (tentative)
Listing exchanges	BSE and NSE
Post-issue market capitalisation	Approximately ₹7,498 crore
QIB reservation	75%
NII reservation	15%
Retail reservation	10%

The minimum retail application is 21 shares, requiring ₹14,553 at the upper price band of ₹693.

The IPO was initially proposed at ₹1,800 crore in the Draft Red Herring Prospectus (DRHP). The issue size was subsequently reduced to ₹1,450 crore, primarily through a reduction in the OFS component.

Get the latest updates on the Paras Healthcare IPO, including issue details, price band, subscription status and key valuation metrics.

Paras Healthcare IPO Issue Structure

Of the total ₹1,450 crore IPO, ₹500 crore represents fresh equity capital, while ₹950 crore is being offered by existing shareholders.

This distinction matters because only fresh issue proceeds become available to the company for business purposes.

Fresh Issue vs Offer for Sale

Fresh issue	₹500 crore (34.48%)
Offer for Sale	₹950 crore (65.52%)

Approximately 65.52% of the IPO represents an exit by existing shareholders, while 34.48% will provide fresh capital to Paras Healthcare.

Who Is Selling Shares in the IPO?

Two major existing shareholders are participating in the OFS.

Selling shareholder	OFS amount
Dr Dharminder Kumar Nagar	Up to ₹300 crore
Commelina Ltd	Up to ₹650 crore
Total	₹950 crore

Dr Dharminder Kumar Nagar is the company's promoter, while Commelina Ltd is affiliated with Malaysian private equity firm Creador.

Pre-IPO Shareholding Structure

The company's ownership before the IPO was concentrated among its promoter and institutional investors.

Shareholder	Pre-IPO holding
Dr Dharminder Kumar Nagar	72.80%
Commelina Ltd	16.44%
360 ONE	6.37%
Axis New Opportunities AIF	3.63%

The large OFS does not directly weaken the company's operations. However, it means a significant portion of investors' IPO capital will go to selling shareholders rather than funding business expansion.

Paras Healthcare IPO Objectives and Use of Proceeds

Paras Healthcare intends to use most of its ₹500 crore fresh issue proceeds to repay existing borrowings.

The company has allocated ₹375 crore towards debt reduction, representing 75% of the fresh issue.

Proposed utilisation	Amount
Repayment or prepayment of company borrowings	₹320.90 crore
Investment in PMHPL for debt repayment	₹54.10 crore
General corporate purposes	₹125 crore
Total	₹500 crore

How Will Debt Repayment Benefit Paras Healthcare?

The planned repayment can improve the company's financial position in three ways:

• Lower borrowings: Repayment of ₹375 crore will reduce outstanding debt and financial leverage.

• Lower interest burden: Reduced borrowings may help lower finance costs, supporting future profitability.

• Improved financial flexibility: A stronger balance sheet could provide additional capacity to support future operations and expansion.

However, the fresh issue does not directly allocate capital towards constructing new hospitals.

Projects such as Gurugram II and Ludhiana will therefore depend on internal cash generation and additional financing.

About Paras Healthcare Ltd

Paras Healthcare Ltd operates a network of multispecialty hospitals focused on providing tertiary and specialised healthcare services.

The company operates eight hospitals across North India, Bihar and Jharkhand, with a combined installed capacity of 2,211 beds.

Of these, 1,502 beds were operational during the reported period.

Paras Healthcare Business Model

The company generates revenue primarily through inpatient and outpatient medical services, including specialised procedures, surgeries, diagnostics and hospital-based treatments.

Its major clinical specialties include:

• Cardiac sciences
• Oncology
• Neurosciences
• Gastroenterology
• Orthopaedics
• Renal sciences

These six specialties collectively contributed 74.70% of revenue in FY26, highlighting the company's focus on specialised healthcare services.

Geographic Revenue Mix

Paras Healthcare has a meaningful presence in Tier-2 healthcare markets.

These markets contributed 68.18% of the company's FY26 revenue.

This positioning provides access to patient demand outside major metropolitan areas. However, the company's financial performance still depends on hospital occupancy, treatment volumes, pricing and operating efficiency.

Paras Healthcare Financial Performance

Paras Healthcare recorded strong revenue growth in FY26 and returned to profitability after reporting losses in FY24 and FY25.

Revenue from operations increased from ₹1,294.06 crore in FY25 to ₹1,605.95 crore in FY26, representing growth of approximately 24.10%.

Revenue and Profit Growth: FY24 to FY26

The tables below compare Paras Healthcare's financial performance across FY24, FY25 and FY26, highlighting revenue growth, profitability and changes in debt levels.

FY24 Financial Performance

Particulars	FY24
Revenue from operations	₹1,129.04 crore
Total income	₹1,151.02 crore
EBITDA	₹154.41 crore
EBITDA margin	13.42%
Net loss	₹15.33 crore
Reported RoE	8.32%
Debt-to-equity ratio	2.73x

FY25 Financial Performance

Particulars	FY25
Revenue from operations	₹1,294.06 crore
Total income	₹1,314.21 crore
EBITDA	₹156.46 crore
EBITDA margin	11.91%
Profit/(loss) after tax	-₹57.98 crore
Return on equity	-18.73%
Debt-to-equity ratio	4.39x

FY26 Financial Performance

Particulars	FY26
Revenue from operations	₹1,605.95 crore
Total income	₹1,628.78 crore
EBITDA	₹335.58 crore
EBITDA margin	20.60%
Profit/(loss) after tax	₹43.83 crore
Return on equity	12.98%
Debt-to-equity ratio	3.53x

Paras Healthcare's revenue and operating profitability improved in FY26, with EBITDA more than doubling and the company returning to profitability. However, the FY24 reported RoE of 8.32% should be verified against the underlying financial statements, as the same data reports a net loss.

Revenue Growth vs EBITDA Growth

Between FY24 and FY25, revenue increased, but EBITDA remained nearly unchanged. This indicates that higher business volumes did not initially translate into proportionate operating profits.

The situation changed in FY26, when stronger revenue growth was accompanied by a substantial improvement in EBITDA.

Why Did EBITDA Margin Improve in FY26?

Paras Healthcare's reported EBITDA margin increased from 11.91% in FY25 to 20.60% in FY26, an expansion of 869 basis points.

The improvement was supported by higher hospital occupancy and a reduction in certain operating expenses as a percentage of revenue.

One important factor was the decline in doctor retainer and consultant costs.

Cost metric	FY25/FY26
Doctor retainer and consultant costs as % of revenue	27.74% / 24.54%

This reduction represented approximately ₹51.39 crore of benefit relative to FY26 revenue.

For comparison, the company's FY26 profit before tax was ₹76.03 crore.

The size of this cost improvement illustrates how sensitive reported profitability is to medical professional expenses.

Other contributing factors included bringing certain radiology services in-house and a reduction in receivables loss allowance.

However, not all these benefits can necessarily be repeated at the same rate.

Medical professional attrition reached 61.24% in FY26, making staff retention and cost normalisation important factors for future margins.

Q1 FY27 Financial Performance

Paras Healthcare's profitability improved further during the quarter ended 30 June 2026.

Particulars	Q1 FY27
Total income	₹478.75 crore
Profit after tax	₹49.68 crore

The company earned ₹49.68 crore in Q1 FY27, exceeding its entire FY26 net profit of ₹43.83 crore.

This is a significant development because it indicates that the improvement in operating performance continued beyond FY26.

However, one quarter of earnings does not establish a sustainable annual profit level. Investors need to assess whether higher occupancy, operating margins and cost efficiencies continue in subsequent quarters.

Hospital Occupancy and ARPOB Analysis

Hospital occupancy and Average Revenue Per Occupied Bed (ARPOB) are two important operating indicators for analysing Paras Healthcare.

Occupancy measures the percentage of available operational bed capacity utilised by patients.

ARPOB measures the average daily revenue generated from each occupied bed.

Together, these indicators help explain whether hospital revenue growth is being driven by patient volumes, pricing or treatment mix.

Hospital Occupancy Trend

Paras Healthcare recorded a substantial improvement in occupancy during FY26 and Q1 FY27.

Period	Occupancy
FY24	52.46%
FY25	50.78%
FY26	61.75%
Q1 FY27	69.72%

Occupancy increased by 10.97 percentage points in FY26 and improved further by 7.97 percentage points in Q1 FY27.

Higher occupancy can improve hospital profitability because fixed expenses such as infrastructure, equipment and administrative costs are distributed across more occupied beds.

Occupied Bed Days and ARPOB

The following operating metrics show how patient volumes and revenue per bed have changed.

Occupied Bed Days

Period	Occupied Bed Days
FY24	254,716
FY25	268,927
FY26	338,321
Q1 FY27	95,272

ARPOB

Period	ARPOB
FY24	₹44,305.65
FY25	₹48,088.57
FY26	₹47,397.82
Q1 FY27	₹49,351.70

What Drove Hospital Revenue Growth?

Paras Healthcare's FY26 growth was primarily volume-led rather than price-led.

• Occupied bed days increased 25.81%, indicating higher patient utilisation.

• ARPOB declined 1.44%, showing that revenue per occupied bed did not increase alongside patient volumes.

• Occupancy reached 61.75%, supporting stronger operating leverage and profitability.

This distinction is important.

Higher patient volumes can increase revenue and improve fixed-cost absorption. However, sustained earnings growth also depends on maintaining healthy revenue realisations per patient.

In Q1 FY27, ARPOB improved to ₹49,351.70, while occupancy reached 69.72%.

If both metrics remain strong, the company could benefit from a combination of higher utilisation and improved revenue per occupied bed.

Paras Healthcare Debt and Cash Flow Analysis

Despite improving profitability, Paras Healthcare continues to carry substantial borrowings.

Its hospital expansion and capital expenditure requirements have historically exceeded operating cash generation, resulting in additional borrowing.

Borrowings Trend

Period	Total borrowings
31 March 2025	₹1,232.12 crore
31 March 2026	₹1,393.86 crore
30 June 2026	₹1,429.49 crore

Borrowings increased by approximately ₹161.74 crore during FY26 and rose further by June 2026.

Operating Cash Flow vs Capital Expenditure

Between FY24 and FY26, Paras Healthcare generated ₹342.18 crore from operating activities while spending ₹503.64 crore on capital expenditure.

Capital expenditure exceeded operating cash generation by ₹161.46 crore.

This gap illustrates why the company has relied on external financing to support its investments.

How Much Debt Will Remain After the IPO?

Paras Healthcare plans to utilise ₹375 crore of IPO proceeds towards debt repayment.

Based on borrowings of ₹1,429.49 crore as of 30 June 2026, a simple illustrative calculation gives:

Particulars	Amount
Borrowings as of 30 June 2026	₹1,429.49 crore
Proposed debt repayment	₹375 crore
Illustrative remaining borrowings	₹1,054.49 crore

This is an illustrative calculation, not a forecast of the actual post-IPO borrowing balance. It excludes subsequent borrowing movements, repayment timing and other adjustments.

The supplied adjusted debt-to-equity estimate is approximately 1.15x after the proposed repayment.

Therefore, the IPO should improve the company's leverage position, but it will not eliminate debt-related risk.

Finance Cost Coverage

In FY26, Paras Healthcare reported:

• EBITDA of ₹335.58 crore

• Finance costs of ₹115.98 crore

• EBITDA-to-finance-cost coverage of approximately 2.89x

This means annual EBITDA was approximately 2.89 times reported finance costs.

While the company generated enough EBITDA to cover its interest and other finance costs on this measure, the remaining earnings must also support depreciation, taxation, working capital and capital expenditure.

Receivables and Government-Payor Risk

Paras Healthcare's revenue mix has become increasingly dependent on government schemes and public sector undertakings.

Their contribution increased from 29.76% in FY24 to 43.63% in Q1 FY27.

Government-linked payors can support patient volumes but may involve administered treatment rates and longer collection periods.

The company's net receivables increased from approximately 50.50 days of revenue in FY24 to 86.60 days by 30 June 2026.

A longer receivables cycle can create working capital pressure even when reported profits are improving.

Paras Healthcare IPO Valuation and Peer Comparison

The Paras Healthcare IPO price at the upper band is ₹693 per share, implying a post-issue market capitalisation of approximately ₹7,498 crore.

The company's valuation appears particularly high when compared with its FY26 reported earnings.

Paras Healthcare IPO P/E Ratio

Valuation metric	Estimate
Upper IPO price band	₹693
Post-issue market capitalisation	₹7,498 crore
FY26 PAT	₹43.83 crore
Trailing P/E	171.09x
Annualised Q1 FY27 PAT	₹198.72 crore
P/E on annualised Q1 PAT	Approximately 37.7x

At 171.09x FY26 earnings, investors are paying a high multiple for a company that has only recently returned to profitability.

However, annualising Q1 FY27 PAT produces a different picture.

The company reported ₹49.68 crore PAT during Q1 FY27. Multiplying this by four gives an illustrative annual profit of ₹198.72 crore.

At the same market capitalisation, the implied P/E falls to approximately 37.7x.

This lower multiple depends entirely on whether Q1 profitability can be sustained throughout the year.

Paras Healthcare vs Listed Hospital Peers

The following comparison places Paras Healthcare's FY26 valuation alongside selected listed healthcare companies.

Company	FY26 revenue/P/E
Paras Healthcare	₹1,605.95 cr / 171.09x
Aster DM Quality Care	₹4,643.22 cr / 91.89x
Jupiter Lifeline Hospitals	₹1,499.79 cr / 42.92x
Krishna Institute of Medical Sciences	₹3,904.60 cr / 116.41x

Paras Healthcare commands the highest P/E multiple among the companies in this comparison.

Its valuation is substantially above Jupiter Lifeline Hospitals and Aster DM Quality Care, despite having a smaller revenue base than Aster DM Quality Care and Krishna Institute of Medical Sciences.

However, P/E ratios alone do not establish whether a hospital company is overvalued. Differences in profitability, hospital maturity, leverage, expansion plans and growth expectations also influence valuation.

What Does the Valuation Mean for Investors?

The key issue is the gap between historical and recent profitability.

On FY26 earnings, the valuation is demanding. On annualised Q1 FY27 earnings, it appears considerably lower.

For the valuation to become more comfortable, Paras Healthcare would need to demonstrate:

• Sustained hospital occupancy and patient-volume growth.

• Stable or improving ARPOB.

• Continued operating margin improvement.

• Lower finance costs following debt repayment.

• Stronger cash conversion and controlled receivables.

• Successful utilisation of existing and planned hospital capacity.

The company's next quarterly results will therefore be important for assessing whether recent earnings represent a sustainable improvement.

Growth Opportunities and Expansion Plans

Paras Healthcare has growth opportunities from both existing hospital capacity and planned expansion projects.

The company has 2,211 installed beds, of which 1,502 were operational during the reported period.

This leaves approximately 709 beds that were not yet operational.

Existing Hospital Capacity

Capacity metric	Beds
Total installed capacity	2,211
Operational beds	1,502
Beds not yet operational	709
Average occupied beds in Q1 FY27	Approximately 1,047

Average occupied beds represented approximately 47.36% of total installed capacity in Q1 FY27.

This is different from the reported hospital occupancy rate of 69.72%, which is calculated using operational bed capacity.

The distinction matters because the company has potential to increase patient volumes by commissioning existing non-operational capacity.

Upcoming Hospital Expansion

Paras Healthcare is also pursuing additional capacity through:

• Kanpur: Approximately 300 beds within the existing non-operational capacity.

• Gurugram II: A planned 300-bed hospital.

• Ludhiana: Additional hospital expansion.

These projects could support revenue growth over time, provided the company can commission capacity, attract patients and achieve commercially sustainable occupancy levels.

However, expansion also involves funding requirements.

The company's undiscounted lease commitments stood at ₹1,054.78 crore, indicating substantial contractual obligations.

Since most fresh IPO proceeds are earmarked for debt repayment, future projects will require cash generated by the business or additional financing.

Paras Healthcare IPO GMP

The Paras Healthcare IPO GMP, or Grey Market Premium, is an unofficial indicator of market sentiment before listing.

Reports around 19 October 2026 indicated a grey market premium of approximately ₹92 per share.

Particulars	Indicative value
Upper IPO price	₹693
Reported GMP	₹92
Indicative listing price	₹785
Indicative premium	13.3%

The indicative listing price is calculated by adding the reported GMP to the upper IPO price.

₹693 + ₹92 = ₹785

This implies an indicative premium of approximately 13.3%.

However, GMP is not an official exchange price and can change substantially before listing.

Investors should not interpret it as a guarantee of listing gains or evidence of the company's long-term valuation.

Strengths and Key Risks

Paras Healthcare has demonstrated improving operating performance, but its financial position and valuation require careful assessment.

Key Strengths of Paras Healthcare

1. Strong revenue growth: Revenue from operations increased 24.10% in FY26, supported by higher patient volumes.

2. Improving hospital utilisation: Occupancy rose from 50.78% in FY25 to 69.72% in Q1 FY27.

3. Return to profitability: PAT improved from a ₹57.98 crore loss in FY25 to a ₹43.83 crore profit in FY26.

4. Strong Q1 FY27 earnings: Quarterly PAT of ₹49.68 crore exceeded the company's full-year FY26 profit.

5. Available hospital capacity: Around 709 installed beds were not yet operational, providing potential for higher utilisation.

6. Debt reduction: The proposed ₹375 crore repayment can reduce leverage and future finance costs.

7. Specialty-focused operations: Six core clinical specialties contributed 74.70% of FY26 revenue.

Key Risks of Paras Healthcare IPO

1. High valuation

The IPO is priced at approximately 171.09x FY26 earnings. Such a high multiple leaves limited room for weaker-than-expected profitability.

2. Large Offer for Sale

The ₹950 crore OFS accounts for approximately 65.52% of the issue. These proceeds will go to existing shareholders rather than the company.

3. Significant borrowings

Total borrowings reached ₹1,429.49 crore by June 2026. Although IPO proceeds will reduce debt, leverage remains an important financial risk.

4. Government-payor dependence

Government schemes and PSUs contributed 43.63% of Q1 FY27 revenue. Greater dependence on these payors may affect revenue realisations and payment timelines.

5. Increasing receivables

Net receivables increased to approximately 86.60 days of revenue by June 2026, compared with 50.50 days in FY24. Slower collections could increase working capital requirements.

6. Margin sustainability

FY26 margin expansion benefited from lower medical professional expenses, insourcing and reduced receivables loss allowance. These improvements may not recur at the same pace.

7. Medical professional attrition

Attrition of 61.24% in FY26 creates uncertainty around staffing continuity and future medical professional costs.

8. Expansion execution

Gurugram II, Ludhiana and existing unoperational capacity require successful commissioning, funding and patient acquisition. The company's substantial lease commitments add to its financial obligations.

Interested in applying for the Paras Healthcare IPO? Apply online through Zerodha.

Paras Healthcare IPO Review: What Investors Should Track

Paras Healthcare's investment case depends on whether its improving operating performance can translate into sustained profitability and stronger cash generation.

The company has demonstrated higher hospital occupancy, better operating margins and a return to profitability. However, these improvements must be considered alongside its premium valuation, debt burden and rising receivables.

Bull Case vs Bear Case

Bull case	Bear case
Higher occupancy improves operating leverage	Occupancy growth slows
709 unoperational beds provide capacity headroom	New beds take longer to become profitable
Q1 FY27 earnings momentum continues	FY26 margin improvements prove difficult to sustain
IPO proceeds reduce finance costs	Borrowings and lease commitments remain substantial
Specialty services support patient demand	Government-payor mix pressures realisations and collections

Important Indicators to Monitor After Listing

Investors evaluating Paras Healthcare's future performance should focus on the following indicators:

• Hospital occupancy: Whether the company can sustain occupancy near Q1 FY27 levels as capacity expands.

• ARPOB: Whether revenue per occupied bed continues improving from ₹49,351.70 in Q1 FY27.

• EBITDA margin: Whether the FY26 margin of 20.60% remains sustainable.

• Profitability: Whether quarterly PAT continues to support the lower annualised earnings multiple.

• Debt reduction: The actual reduction in borrowings and finance costs after IPO proceeds are utilised.

• Receivables: Whether collection periods stabilise or improve from 86.60 days.

• Government-payor revenue: Changes in the contribution from government schemes and PSUs.

• Capacity expansion: Progress in operationalising the 709 existing beds and executing the Gurugram II and Ludhiana projects.

• Operating cash flow: Whether internal cash generation can support future capital expenditure without substantial additional borrowing.

Conclusion

The Paras Healthcare IPO combines strong recent operating growth with a demanding valuation and a leveraged balance sheet.

Revenue increased 24.10% in FY26, hospital occupancy improved to 69.72% in Q1 FY27, and quarterly PAT of ₹49.68 crore exceeded the previous full-year profit. These developments indicate meaningful progress in the company's operating performance.

However, the IPO's 171.09x trailing P/E, ₹950 crore OFS, significant borrowings and increasing receivables remain important concerns.

For investors, the central question is whether the company's recent profitability can be sustained as it expands hospital capacity and reduces debt. Upcoming quarterly results, particularly occupancy, ARPOB, operating margins, cash flow and finance costs, will provide greater clarity.

Want to compare Paras Healthcare's valuation with other recent healthcare and hospital-sector offerings? Use this IPO dashboard to review issue sizes, price bands, subscription trends and listing details across companies.

Frequently Asked Questions

1. What is the Paras Healthcare IPO date and price band?

The Paras Healthcare IPO opens on 21 October 2026 and closes on 23 October 2026. Its price band is ₹660 to ₹693 per share, with a lot size of 21 shares. The minimum retail investment is ₹14,553 at the upper price band.

2. What is the Paras Healthcare IPO GMP today?

As of reports around 19 October 2026, the Paras Healthcare IPO GMP was approximately ₹92 per share. At the upper price band of ₹693, this implies an indicative listing price of ₹785, or a premium of about 13.3%. GMP is unofficial, volatile and does not guarantee listing returns.

3. Is Paras Healthcare profitable?

Yes. Paras Healthcare reported a net profit of ₹43.83 crore in FY26 after losses of ₹57.98 crore in FY25 and ₹15.33 crore in FY24. Profitability improved further in Q1 FY27, when PAT reached ₹49.68 crore.

4. How will Paras Healthcare use its IPO proceeds?

Paras Healthcare plans to raise ₹500 crore through fresh equity shares. Of this, ₹320.90 crore will be used to repay company borrowings, ₹54.10 crore will be invested in subsidiary PMHPL for debt repayment, and ₹125 crore will be allocated to general corporate purposes. The remaining ₹950 crore of the IPO is an OFS.

5. Is Paras Healthcare IPO good for long-term investors?

Paras Healthcare offers potential growth from higher hospital occupancy, unused bed capacity and improving profitability. However, its high trailing P/E of 171.09x, substantial borrowings, rising receivables and margin sustainability risks require consideration. Long-term investment outcomes will depend on whether the company can sustain earnings growth, reduce leverage and generate stronger operating cash flow.